Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases has announced that it has entered into a definitive agreement for Johnson & Johnson to acquire Momenta for US$52.50 per share in an all-cash transaction, implying a fully-diluted equity value of US$6.5 billion. The agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson.

Latham & Watkins LLP advised Momenta Pharmaceuticals, Inc. in the transaction with a corporate deal team led by partners Scott Shean and Peter Handrinos, with associates Darren Guttenberg, Christopher Lee, Shannon Cheng, and Christopher Martinez. Advice was also provide on antitrust matters by partner Michael Egge and counsel Patrick English, with associate Barrett Tenbarge; on benefits and compensation matters by partner Matthew Conway, with associate Nikhil Kumar; on tax matters by partner Lisa Watts, with associate Shruti Hazra; on intellectual property matters by partner Alan Tamarelli; on regulatory matters by partner Elizabeth Richards and counsel Betty Pang, with associate Nathan Beaton; and on general corporate matters by partner Jenna Cooper.